Successful dupilumab treatment for omalizumab-refractory chronic spontaneous urticaria with GATA3+ cell infiltration
European Journal of Dermatology · 2026-06 · 36 (3) · 277-279
DOI: 10.1684/ejd.2026.5084 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Dermatology, 2026-06. Verfasst von Kaho Shirai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Deprtment of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Deprtment of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
- Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Zitieren
APA
Shirai, K., Suzuki, T., Nagakura, Y., & Honda, T. (2026). Successful dupilumab treatment for omalizumab-refractory chronic spontaneous urticaria with GATA3+ cell infiltration. European Journal of Dermatology, 36(3), 277-279. https://doi.org/10.1684/ejd.2026.5084
Vancouver
Shirai K, Suzuki T, Nagakura Y, Honda T. Successful dupilumab treatment for omalizumab-refractory chronic spontaneous urticaria with GATA3+ cell infiltration. European Journal of Dermatology. 2026;36(3):277-279. doi:10.1684/ejd.2026.5084
BibTeX
@article{Shirai2026,
author = {Shirai, Kaho and Suzuki, Takahiro and Nagakura, Yuka and Honda, Tetsuya},
title = {Successful dupilumab treatment for omalizumab-refractory chronic spontaneous urticaria with GATA3+ cell infiltration},
journal = {European Journal of Dermatology},
year = {2026},
volume = {36},
number = {3},
pages = {277--279},
doi = {10.1684/ejd.2026.5084}
}
EUVIMED